<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04459338</url>
  </required_header>
  <id_info>
    <org_study_id>20-003995</org_study_id>
    <nct_id>NCT04459338</nct_id>
  </id_info>
  <brief_title>A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion</brief_title>
  <official_title>A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Vella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in&#xD;
      the control of blood sugar level by enhancing insulin secretion from the pancreas after&#xD;
      eating a meal. The purpose of this research study is to evaluate the role of GLP1R in the&#xD;
      response to elevated glucagon concentrations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucagon within the islet can signal the β-cell through GLP1R, and acts as an insulin&#xD;
      secretagogue. This signaling is blocked by exendin-9,39. The relative importance of glucagon&#xD;
      signaling through its cognate receptor or through GLP1R is unknown. Despite the lower&#xD;
      affinity of GLP1R for glucagon, intra-islet concentrations of glucagon are sufficiently high&#xD;
      to stimulate GLP1R. The other situation where this may occur is in response to pharmacologic&#xD;
      doses of glucagon as used for β-cell function testing or raising peripheral glucagon&#xD;
      concentrations above fasting values. The experiments proposed will characterize the role of&#xD;
      GLP1R in glucagon's actions on the β-cell and the potential therapeutic role of dual (GLP-1R&#xD;
      and glucagon receptor) agonists for the treatment of T2DM and obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-cell responsivity (Φ)</measure>
    <time_frame>It will be quantified hourly during the course of the experiment (0-300 minutes)</time_frame>
    <description>This is an index of insulin secretion calculated using the minimal modelfor the prevailing glucose concentration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infused during the hyperglycemic clamp with escalating doses of glucagon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9,39</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exendin-9,39 infused during the hyperglycemic clamp with escalating doses of glucagon</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Exendin-9,39</intervention_name>
    <description>Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor</description>
    <arm_group_label>Exendin-9,39</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 weight-stable, non-diabetic subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 25 or &gt; 65 years (to avoid studying subjects who could have latent type 1&#xD;
             diabetes, or the effects of age extremes in subjects with normal or impaired fasting&#xD;
             glucose).&#xD;
&#xD;
          -  HbA1c ≥5.9%&#xD;
&#xD;
          -  Use of glucose-lowering agents.&#xD;
&#xD;
          -  For female subjects: positive pregnancy test at the time of enrollment or study&#xD;
&#xD;
          -  History of prior upper abdominal surgery such as adjustable gastric banding,&#xD;
             pyloroplasty and vagotomy.&#xD;
&#xD;
          -  Active systemic illness or malignancy.&#xD;
&#xD;
          -  Symptomatic macrovascular or microvascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy L Zipse</last_name>
      <phone>507-255-0907</phone>
      <email>zipse.amy@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

